For the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors1
HE’S READY TO MOVE ON
For the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors1
HE’S READY TO MOVE ON



References:
- SEVENFACT [Prescribing Information]. HEMA Biologics; 2020.
- FDA ACCEPTS FOR REVIEW LFB’S BLA FOR ITS RECOMBINANT FACTOR VII [news release]. Les Ulis (France). LFB News. https://www.groupe-lfb.com/en/news/fda-accepts-for-review-lfbs-bla-for-its-recombinant-factor-vii/. Accessed November 23, 2020. LFB Groupe. 2017.
- NovoSeven [Prescribing Information]. Novo Nordisk; 2020.
- Biron-Andreani C, Schved J-F. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2019;12(1):21-28.
- Salaj PO, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009;15:752-759.
- Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16:487-494.
- Morfini M. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients. Eur J Haematol. 2016;96:111-118.
- Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014;12(suppl1):s319-s329.
- Data on file. Hema Biologics.